Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia

17 Jul 2025

Abstract excerpt

ABSTRACT: Molecular measurable residual disease (MRD) assessment in patients with acute myeloid leukemia (AML) has been established for only a few specific markers: mutant NPM1 and FLT3 internal tandem duplication (ITD). Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) are present in ∼20% of patients with AML. However, validation of mutant IDH1/2 MRD has been hampered by cohort...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer Genomics and Diagnostics
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40674738
DOI: 10.1182/bloodadvances.2025016726

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemiaPMID 40674738Read ↗

Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemiaSemantic proximity Read ↗

IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?Semantic proximity Read ↗

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.Semantic proximity Read ↗

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia.Semantic proximity Read ↗

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia.Semantic proximity Read ↗

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.Semantic proximity Read ↗

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.Semantic proximity Read ↗

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 ProtocolSemantic proximity Read ↗

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.Semantic proximity Read ↗

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.Semantic proximity Read ↗

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.Semantic proximity Read ↗

Monitoring of measurable residual disease by next‐generation sequencing in patients with acute myeloid leukaemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.